All In Biotech

Drug Trial Radar · NCT02402660

Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Aug 2015

Primary completion

Jun 30, 2028

Study completion Nov 30, 2028

Sponsor

Lead sponsor
Alkeus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Mar 30, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 8 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 8 and 70 years old. Funding Source - FDA OOPD

Conditions

  • Stargardt Disease
  • Stargardt Macular Degeneration
  • Stargardt Macular Dystrophy
  • Autosomal Recessive Stargardt Disease 1 (ABCA4-related)

Interventions

  • ALK-001Drug

    Daily, oral administration for 24 months

  • PlaceboDrug

    Daily, oral administration for 24 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of 24 months of daily dosing of ALK-001 assessed by incidence and/or clinically significant changes of a combination of ocular and non-ocular adverse eventsTime frame: From baseline to 24 months

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Alkeus Site

    Phoenix, Arizona

  • Alkeus Site

    Los Angeles, California

  • Alkeus Site

    Aurora, Colorado

  • Alkeus Site

    Gainesville, Florida

  • Alkeus Site

    Miami, Florida

  • Alkeus Site

    Indianapolis, Indiana

  • Alkeus Site

    Baltimore, Maryland

  • Alkeus Site

    Grand Rapids, Michigan

  • Alkeus Site

    New York, New York

  • Alkeus Site

    Westbury, New York

  • Alkeus Site

    Houston, Texas

  • Alkeus Site

    Salt Lake City, Utah

  • Alkeus Site

    Silverdale, Washington

  • Alkeus Site

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.